Market Overview

Nondaily Smokers Who Switch to 22nd Century's Very Low Nicotine Content Cigarettes Reduce their Consumption by a Staggering 51%

Share:

Intermittent smokers assigned to VLNC cigarettes reduced both the
overall number of cigarettes smoked and the number of days on which they
smoked

22nd Century Group, Inc. (NYSE American: XXII),
a plant biotechnology company that is a leader in tobacco harm reduction
and Very Low Nicotine tobacco, announced today that an independent
clinical trial
published this summer in JAMA Psychiatry (a
specialty journal of the American Medical Association) found that
nondaily smokers who switch to 22nd Century's proprietary Very Low
Nicotine Content (VLNC) cigarettes "reduced their smoking by 51%."

In conducting this important clinical trial, study authors Saul
Shiffman, Ph.D., Brenda Kurland, Ph.D., Sarah Scholl, MPH, and Jason
Mao, B.S. used 22nd Century's proprietary SPECTRUM® VLNC cigarettes and
standard nicotine content cigarettes. The 12-week, randomized,
controlled, double-blind intervention trial enrolled 297 adult U.S.
smokers who do not smoke daily; this clinical trial is the first
published study to focus on occasional (nondaily or "intermittent")
smokers.

Intermittent smokers assigned to VLNC cigarettes reduced both the
overall number of cigarettes smoked and the number of days on which they
smoked. Reporting that 25% to 33% of all U.S. smokers do not smoke daily
(intermittent smokers), Dr. Shiffman, et al. believe that this
substantial fraction of the smoking public must be included in all
tobacco policy considerations.

The researchers reported that their study results did not vary by sex or
race/ethnicity. Dr. Shiffman, et al. reported further that their
study results "mitigate concern that intermittent smokers might increase
smoking when switched to Very Low Nicotine Content cigarettes," and that
intermittent smokers "respond to Very Low Nicotine Content cigarettes in
a manner similar to daily smokers, suggesting that a universal policy
[by FDA] is possible."

"The Shiffman clinical study shows that when nicotine is largely absent
from cigarettes, occasional smokers – just like daily smokers – consume
drastically fewer cigarettes," explained Henry Sicignano, III, President
and Chief Executive Officer of 22nd Century Group. "22nd Century is
proud to be at the center of a national policy initiative designed to
ensure that all cigarettes sold in the United States are minimally or
non-addictive; it is imperative that we take this important step to
prevent millions of today's youth from becoming addicted to cigarettes."

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company focused on technology
which allows it to increase or decrease the level of nicotine in tobacco
plants and the level of cannabinoids in hemp/cannabis plants through
genetic engineering and plant breeding. The Company's primary mission in
tobacco is to reduce the harm caused by smoking. The Company's primary
mission in hemp/cannabis is to develop proprietary hemp strains for
important new medicines and agricultural crops. Visit www.xxiicentury.com
and www.botanicalgenetics.com
for more information.

Cautionary Note Regarding Forward-Looking Statements: This
press release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc., its
directors or its officers with respect to the contents of this press
release, including but not limited to our future revenue expectations.
The words "may," "would," "will," "expect," "estimate," "anticipate,"
"believe," "intend" and similar expressions and variations thereof are
intended to identify forward-looking statements. We cannot guarantee
future results, levels of activity or performance. You should not place
undue reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should be
considered with any written or oral forward-looking statements that we
may issue in the future. Except as required by applicable law, including
the securities laws of the United States, we do not intend to update any
of the forward-looking statements to conform these statements to reflect
actual results, later events or circumstances, or to reflect the
occurrence of unanticipated events. You should carefully review and
consider the various disclosures made by us in our annual report on Form
10-K for the fiscal year ended December 31, 2017, filed on March 7,
2018, including the section entitled "Risk Factors," and our other
reports filed with the U.S. Securities and Exchange Commission which
attempt to advise interested parties of the risks and factors that may
affect our business, financial condition, results of operation and cash
flows. If one or more of these risks or uncertainties materialize, or if
the underlying assumptions prove incorrect, our actual results may vary
materially from those expected or projected.

View Comments and Join the Discussion!